The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...

NEW YORK, Dec 27 (Reuters) - A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis (NOVN.S), opens new tab of paying illegal kickbacks to doctors to ...

"This collaboration with Novartis showcases the value of our platform ... He spent a year abroad as business editor at The Prague Post. Ron earned his journalism degree from Eastern Michigan ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. Novartis confirmed ...

Swiss pharmaceutical company Novartis plans to close MorphoSys sites in the U.S. and Germany in a “strategic decision” that will affect 330 jobs. The move, which was first reported by the German ...

Credit: Dragana Gordic/Shutterstock. BioAge Labs has entered a multi-year research partnership with Novartis to discover and validate new therapeutic drug targets that address ageing-related diseases.

Novartis is closing down sites in Germany and Boston that were picked up in its $2.9 billion acquisition of MorphoSys, Reuters reported Thursday. The move will result in layoffs affecting 330 jobs. A ...

BioAge Labs, which be­gan near­ly a decade ago as an an­ti-ag­ing biotech and then turned to obe­si­ty this year, is go­ing back to its roots … ...

Freshly public BioAge Labs has secured a multiyear partnership with Novartis that focuses on age-related diseases and includes the possibility of up to $550 million in biobucks. The freshly inked ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other oversold global stocks. 'There are decades where nothing happens, and there are weeks where ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral asset—dubbed minzasolmin—missed the study’s ...